science wire

« BACK

Pharmacology



Results 451 - 500 of 1332.
« Previous 1 ... 6 7 8 9 10 11 12 13 14 ... 27 Next »


Health - Pharmacology - 23.10.2017
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients Breakthrough Therapy Designation ba

Health - Pharmacology - 18.10.2017
Novartis drug Revolade shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
Nearly 70% of patients maintained platelet counts of >=30◊10 9 /L without rescue therapy for prolonged periods, reducing the overall risk of bleeding † More than one-third of patients permanently

Health - Pharmacology - 16.10.2017
Endogenous Infection Marker Guides Antibiotic Therapy
The endogenous infection marker procalcitonin can help to guide the use of antibiotics when treating infections.

Pharmacology - Health - 28.09.2017
Novartis and UC Berkeley collaborate to tackle ’undruggable’ disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer   New Novartis-Berkeley Center for Proteomics and Ch

Health - Pharmacology - 26.09.2017

Pharmacology - Health - 26.09.2017
Even Open-Label Placebos Work - if They Are Explained
Even Open-Label Placebos Work - if They Are Explained
For some medical complaints, open-label placebos work just as well as deceptive ones. As psychologists from the University of Basel and Harvard Medical School report in the journal Pain, the accompanying rationale plays an important role when administering a placebo. The successful treatment of certain physical and psychological complaints can be explained to a significant extent by the placebo effect.

Pharmacology - Health - 22.09.2017
Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people wit

Pharmacology - Health - 22.09.2017
Roche receives European approval for Actemra /RoActemra in giant cell arteritis
Roche receives European approval for Actemra /RoActemra in giant cell arteritis Actemra/RoActemra is the first therapy approved for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The approval was based on the outcome of the phase III GiACTA study Roche announced today that the European Commission (EC) has approved Actemra /RoActemra (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.

Pharmacology - Health - 22.09.2017
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche announced today that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chemotherapy, followed by Gazyvaro maintenance in people achieving a response, as a new treatment for previously untreated advanced follicular lymphoma.

Health - Pharmacology - 22.09.2017
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model † GIPAP was introduced 15 years ago and has provi

Health - Pharmacology - 20.09.2017
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis drug Rydapt (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Significant overall surviv

Pharmacology - Health - 18.09.2017
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche announced today that the phase III MURANO study, which evaluated Venclexta /Venclyxto (venetocla

Pharmacology - Health - 16.09.2017
Novartis’ Xolair confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled † Should a treatment pause be necessary, data showed almost 90% of chronic spontaneous urticaria (CSU) patients - previously well controlled - regained effective symptom control within 12 weeks of re-treatment on Xolair † Previous studies have shown that inadequately controlled CSU has a major impact on sleep, social l

Health - Pharmacology - 15.09.2017
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
New Study on the Placebo Effect and Antidepressants in Children and Adolescents
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects. In addition, the influence of the placebo effect on the efficacy of antidepressants is unclear. A meta-analysis of data from over 6,500 patients has now shown that, although antidepressants are more effective than placebos, the difference is minor and varies according to the type of mental disorder.

Health - Pharmacology - 14.09.2017
Parasitic Worms in Siberia
Parasitic Worms in Siberia
Millions of people worldwide are infected with parasitic worms, most of them in tropical low-income settings.

Health - Pharmacology - 14.09.2017
Increase of antibiotic resistance - Antibiotic Awareness Week highlights the risks
Bern, 14.09.2017 - The global fight against antibiotic resistance is ramping up. The World Health Organization has launched an Antibiotic Awareness Week, which will be running for the first time in Switzerland from 13 to 19 November 2017.

Pharmacology - Health - 14.09.2017
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira * safety and efficacy profile Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases Holzkirchen, Septem

Health - Pharmacology - 13.09.2017
Vessels that help cancers spread can also boost cancer immunotherapy
Vessels that help cancers spread can also boost cancer immunotherapy
Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. Many cancers, such as melanoma, are known to metastasize and spread by expanding nearby lymphatic vessels. This process, lymphangiogenesis, also helps the tumor evade the patient's own immune system, and it would be expected that inhibiting lymphangiogenesis, could enhance the efficacy of cancer immunotherapies, which are only effective in a minority of patients.

Pharmacology - Health - 13.09.2017
Novartis’ Cosentyx sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx (secukinumab) is the first and only fully human IL-17A † inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis † Landmark data show that PASI 90 and PASI 100

Pharmacology - Health - 12.09.2017
Sandoz proposed biosimilar rituximab accepted for review by the FDA
Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our

Pharmacology - Health - 11.09.2017
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma
Roche announces phase III study results of Zelboraf for adjuvant treatment of BRAF V600 mutation-positive melanoma Roche today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf (vemurafenib) in the adjuvant (after surgery) treatment of people with completely resected, BRAF V600 mutation-positive melanoma.

Health - Pharmacology - 11.09.2017
Adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
Novartis Phase III study demonstrates adjuvant Tafinlar + Mekinist reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma The three-year relapse

Health - Pharmacology - 09.09.2017
Novartis presents new data at EURETINA 2017 confirming Lucentis efficacy and durability vs aflibercept
Interim results of the head-to-head RIVAL study confirm strong efficacy and comparable durability versus aflibercept in patients with nAMD † Five-year results from the Lucentis LUMINOUS study, the largest ever in retinal disease, demonstrate real-world efficacy and safety across five retinal diseases Novartis, the global leader in ophthalmology, today reported new data confirming Lucentis (ranibizumab) efficacy and durability in patients with nAMD at the 17 th EURETINA Congress in Barcelona, Spain (September 7-10, 2017).

Health - Pharmacology - 08.09.2017
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration
Roche provides update on first lampalizumab phase III study for geographic atrophy, an advanced form of age-related macular degeneration Spectri study did not meet its primary endpoint of reducing mean change in geographic atrophy lesion area in patients treated with lampalizumab compared with sham treatment Safety profile was in line with previous lampalizumab trials and other intravitreal therapies Results from the second phase III study, Chro

Pharmacology - Health - 08.09.2017
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress
Roche announces progress in biomarker science in cancer immunotherapy at the European Society for Medical Oncology Congress First data on new blood-based assay for measuring tumour mutational burden Two prospective studies underway to assess the potential of tumour mutational burden to predict response to certain cancer immunotherapies Roche announced today that the first data on a novel blood-based assay, co-developed with Foundation Medicine (NASDAQ: FMI), will be presented during the European Society for Medical Oncology (ESMO) Congress from 8-12 September 2017 in Madrid, Spain.

Pharmacology - Health - 07.09.2017
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies AMG 334 (erenumab) delivered consistent reductions in monthly migraine days for patients with chronic migraine and prior treatment failure, a population with significant unmet need   Dedicated cardiovascular safety study reaffirmed placebo-like tolerability of erenumab as seen consisten

Pharmacology - Health - 06.09.2017
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer ALUR study shows 85% reduction in risk of disease worsening or death versus chemotherapy in patients with advanced ALK-positive NSCLC who had progressed on chemotherapy and crizotinib Roche today announced results from the global phase III ALUR study showing that Alecensa significantly reduc

Pharmacology - Health - 05.09.2017
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a † There is a significant unmet need for safe and effective MS treatments for children and adolescents, for whom there are no specifically approved disease-modifying therapies † Children and adolescents living with MS†face physical and cognitive disability that severely limits their ability to go about daily activities, such as going to†school † † PARADIGMS is a first of its kind study in pediatric MS.

Business / Economics - Pharmacology - 04.09.2017
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018
Basel, September 4, 2017 - Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, has informed the Board of Directors of his desire to step down as CEO in 2018, after eight years in position.

Health - Pharmacology - 31.08.2017
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress Data from 18 approved and investigational cancer medicines to be presented at ESMO 2017 Results for Zelboraf (vemurafenib) as an adjuvant treatment for BRAF V600 mutation-positive melanoma to feature in the ESMO Presidential Symposium New data from phase III ALEX and ALUR studies provide additional evidence supporting the use o

Health - Pharmacology - 30.08.2017
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice First-in-clas

Health - Pharmacology - 29.08.2017
Combination Therapy to Treat Parasitic Worm Infections
Combination Therapy to Treat Parasitic Worm Infections
1.5 billion people worldwide are infected with soil-transmitted helminths, a parasitic worm infection. In the past, only two drugs have been used, increasing the risk of drug resistance. New drugs and combination therapies are thus urgently needed to fight soil-transmitted helminth infections.

Health - Pharmacology - 27.08.2017
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
Study showed a significant 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis who were treated with 150mg of ACZ885, in addition to standard of care including lipid-lowering therapy   Effect driven by 24% relative reduction in risk of heart attack; a non-significant 10% reduction in risk of cardiovascular death was observed   Sub-group of study participants whose inf

Health - Pharmacology - 27.08.2017
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Review of blinded, pre-planned oncology safety analyses revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases in patients treated with 300mg of ACZ885 CANTOS is the first Phase III clinical trial to support a long-established hypothesis from pre-clinical models

Pharmacology - Health - 24.08.2017
Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis Kisqali (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Approval is based on

Pharmacology - Health - 22.08.2017
Treating arthritis with algae
Researchers at ETH Zurich, Empa and the Norwegian research institute SINTEF are pursuing a new approach to treating arthritis.

Health - Pharmacology - 21.08.2017
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission   KAF156 is first compound fro

Health - Pharmacology - 17.08.2017
Hemorrhagic Fevers: Countering Inflammation to Prevent Circulatory Failure
Hemorrhagic fevers are severe viral diseases that are often fatal. Researchers from the University of Basel have now identified messenger substances of the immune system, which in infected mice lead to the development of shock. These results, published in the scientific journal Cell Host & Microbe, open up new possibilities for the development of life-saving therapies.

Pharmacology - Health - 14.08.2017
Drug Approval: New Country Comparison Shows Great Savings Potential
The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. This reports a study of the European Center of Pharmaceutical Medicine at the University of Basel.

Health - Pharmacology - 03.08.2017
Testing the Limits for the Patients' Benefit
Testing the Limits for the Patients’ Benefit
Radiation therapy using protons is a success story at the Paul Scherrer Institute PSI. For several decades now, doctors have been administering a gentle form of radiation treatment to patients with ocular tumours or those located deep inside the body.

Health - Pharmacology - 25.07.2017
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
Expanded partnership to help "even the odds" of survival for children with cancer in the Philippines, Myanmar, Mexico and Ghana In developed countries, the survival rate for childhood cancer is 80%,

Pharmacology - Health - 21.07.2017
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome of the phase III GiACTA study Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positi

Pharmacology - Health - 21.07.2017
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Novartis receives positive CHMP opinion for Rydapt (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM) Recommendation ba

Chemistry - Pharmacology - 19.07.2017
A uranium-based compound improves manufacturing of nitrogen products
A uranium-based compound improves manufacturing of nitrogen products
EPFL scientists have developed a uranium-based complex that can allow nitrogen fixation reactions to take place in ambient conditions.

Life Sciences - Pharmacology - 18.07.2017
Low-dose diazepam can increase social competitiveness
Low-dose diazepam can increase social competitiveness
EPFL scientists have discovered how low-dose anxiolytics increase the social competitiveness of high-anxious individuals by boosting the energy output of mitochondria in an area of the mammalian brain that controls motivation and reward. Psychologists speak of anxiety in two forms: ‘state' anxiety, which refers to anxiety arising from a particular situation; and ‘trait' anxiety, which refers to anxiety as part of a person's overall personality.

Pharmacology - Business / Economics - 18.07.2017
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
Net sales in line with prior year (0% cc , -2% USD), as growth drivers offset Gleevec/Glivec Gx impact: Cosentyx (USD 490 million, +90% cc) continues strong growth in all three indications Entresto (U

Health - Pharmacology - 17.07.2017
Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia
Roche's OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for peop

Health - Pharmacology - 14.07.2017
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx reinforcing sustained efficacy and safety profile in psoriasis 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis † Data planned to be presented at a key medical congress in the second half of 2017.

Health - Pharmacology - 13.07.2017
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL Recommendation based on review of CTL019 r/r B

Health - Pharmacology - 11.07.2017
Ending Leprosy Transmission
Ending Leprosy Transmission
Despite substantial reduction in prevalence over the past decades, leprosy remains endemic in over 120 countries. Approximately 200,000 new cases of leprosy still occur every year as diagnosis is difficult and often delayed. In an article published on July 7, 2017 in the Lancet Infectious Diseases, the Swiss Tropical and Public Health Institute (Swiss TPH) and its partners reviewed innovative tools and approaches to help end leprosy transmission.
« Previous 1 ... 6 7 8 9 10 11 12 13 14 ... 27 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |
 
/bin/cat /www/cms/admin/geodata/worldcitiespop.txt | egrep -ai '^,' > '/www/cms/admin/geodata/_cities.txt'